BioSpace News Archive

Drug Development

New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies

Novartis announced data from Stage 1 of the National Institutes of Health -sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair® in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine and featured in a late-breaking symposium at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.

February 25, 2024
·
19 min read
Drug Development

Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

Longbio Pharma Co., Ltd. proudly announced the release of preliminary Phase II data for LP-003, the new generation anti-IgE antibody, at the 2024 American Academy of Allergy, Asthma & Immunology annual meeting.

February 25, 2024
·
4 min read
Drug Development

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies

Genentech, a member of the Roche Group, announced data from Stage 1 of the National Institutes of Health -sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair® in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine and featured in a late-breaking symposium at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.

February 25, 2024
·
15 min read
Drug Development

MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd.

AriBio Co., Ltd. receives Notice of Acceptance for POLARIS-AD, a Phase 3 early Alzheimer’s disease clinical trial from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom.

February 25, 2024
·
2 min read